INOGEN, INC. (INGN) Spending and interest coverage
- R&D / revenue · 12 months: Value 6.96%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 2.40%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 6.96% | Research and development expense / revenue. Period ending 2026-06-30. $21.12M ÷ $303.59M × 100 ≈ 6.96% |
| Stock-based compensation / revenue · 12 months | 2.40% | Share-based compensation / revenue. Period ending 2026-06-30. $7.29M ÷ $303.59M × 100 ≈ 2.40% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 21.12M USD | Research and Development Expense |
| Revenue | 303.59M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 7.29M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -30.85M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $21.12M | $303.59M | $7.29M | $-30.85M | (m) | 6.96% | 2.40% | (m) | (m) |
| 2026-03-31 | $20.46M | $299.24M | $7.82M | $-31.89M | (m) | 6.84% | 2.61% | (m) | (m) |
| 2025-12-31 | $19.40M | $295.30M | $8.01M | $-30.21M | (m) | 6.57% | 2.71% | (m) | (m) |
| 2025-09-30 | $19.98M | $293.04M | $7.90M | $-32.29M | (m) | 6.82% | 2.69% | (m) | (m) |
| 2025-06-30 | $18.66M | $288.88M | $7.61M | $-32.96M | (m) | 6.46% | 2.63% | (m) | (m) |
| 2025-03-31 | $19.07M | $284.13M | $7.13M | $-33.90M | (m) | 6.71% | 2.51% | (m) | (m) |
| 2024-12-31 | $21.61M | $278.76M | $7.40M | $-42.52M | (m) | 7.75% | 2.65% | (m) | (m) |
| 2024-09-30 | $22.43M | $271.85M | $4.65M | $-60.11M | (m) | 8.25% | 1.71% | (m) | (m) |
| 2024-06-30 | $23.40M | $264.90M | $4.95M | $-99.04M | (m) | 8.83% | 1.87% | (m) | (m) |
| 2024-03-31 | $22.07M | $258.81M | $6.40M | $-103.75M | (m) | 8.53% | 2.47% | (m) | (m) |
| 2023-12-31 | $20.84M | $251.61M | $7.43M | $-109.39M | (m) | 8.28% | 2.95% | (m) | (m) |
| 2023-09-30 | $20.06M | $265.39M | $11.58M | $-138.89M | (m) | 7.56% | 4.36% | (m) | (m) |
| 2023-06-30 | $20.15M | $288.09M | $13.30M | $-102.46M | (m) | 7.00% | 4.62% | (m) | (m) |
| 2023-03-31 | $21.92M | $309.03M | $13.06M | $-93.57M | (m) | 7.09% | 4.23% | (m) | (m) |
| 2022-12-31 | $21.94M | $320.55M | $12.28M | $-85.24M | (m) | 6.85% | 3.83% | (m) | (m) |
| 2022-09-30 | $20.69M | $310.74M | $11.58M | $-33.43M | (m) | 6.66% | 3.73% | (m) | (m) |
| 2022-06-30 | $19.87M | $301.04M | $10.87M | $-16.76M | (m) | 6.60% | 3.61% | (m) | (m) |
| 2022-03-31 | $17.93M | $302.05M | $11.09M | $-2.21M | (m) | 5.93% | 3.67% | (m) | (m) |
| 2021-12-31 | $16.58M | $311.73M | $10.94M | $9.24M | (m) | 5.32% | 3.51% | (m) | (m) |
| 2021-09-30 | $15.57M | $312.99M | $10.64M | $10.39M | (m) | 4.97% | 3.40% | (m) | (m) |
| 2021-06-30 | $15.32M | $298.82M | $9.90M | $2.04M | (m) | 5.13% | 3.31% | (m) | (m) |
| 2021-03-31 | $14.49M | $274.13M | $7.93M | $-11.98M | (m) | 5.29% | 2.89% | (m) | (m) |
| 2020-12-31 | $14.08M | $280.19M | $8.20M | $-12.03M | (m) | 5.03% | 2.93% | (m) | (m) |
| 2020-09-30 | $14.03M | $289.03M | $8.31M | $-11.82M | (m) | 4.86% | 2.88% | (m) | (m) |
| 2020-06-30 | $13.16M | $308.62M | $7.83M | $-1.74M | (m) | 4.26% | 2.54% | (m) | (m) |
| 2020-03-31 | $11.34M | $338.87M | $8.33M | $12.75M | (m) | 3.35% | 2.46% | (m) | (m) |
| 2019-12-31 | $9.40M | $340.55M | $9.13M | $19.79M | (m) | 2.76% | 2.68% | (m) | (m) |
| 2019-09-30 | $7.51M | $347.81M | $9.94M | $29.89M | (m) | 2.16% | 2.86% | (m) | (m) |
| 2019-06-30 | $6.97M | $351.13M | $11.59M | $32.17M | (m) | 1.99% | 3.30% | (m) | (m) |
| 2019-03-31 | $7.28M | $347.25M | $12.99M | $34.05M | (m) | 2.10% | 3.74% | (m) | (m) |
| 2018-12-31 | $7.03M | $336.01M | $12.79M | $37.89M | (m) | 2.09% | 3.81% | (m) | (m) |
| 2018-09-30 | $6.66M | (m) | $12.79M | $38.31M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $5.93M | (m) | $12.10M | $36.24M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $5.42M | (m) | $11.13M | $30.72M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $5.31M | (m) | $9.64M | $27.59M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $5.16M | (m) | $8.52M | $28.57M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $5.13M | (m) | $7.95M | $25.64M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $5.25M | (m) | $7.89M | $25.16M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $5.11M | (m) | $7.29M | $22.86M | $6.00K | (m) | (m) | 3810.67× | Reported |
| 2016-09-30 | $5.12M | (m) | $6.70M | $20.17M | $10.00K | (m) | (m) | 2016.70× | Reported |
| 2016-06-30 | $4.89M | (m) | $5.76M | $18.48M | $14.00K | (m) | (m) | 1320.29× | Reported |
| 2016-03-31 | $4.49M | (m) | $4.42M | $15.81M | $18.00K | (m) | (m) | 878.33× | Reported |
| 2015-12-31 | $4.18M | (m) | $3.64M | $15.05M | $22.00K | (m) | (m) | 684.14× | Reported |
| 2015-09-30 | $3.62M | (m) | $2.67M | $13.01M | $27.00K | (m) | (m) | 481.81× | Reported |
| 2015-06-30 | $3.30M | (m) | $2.11M | $12.86M | $126.00K | (m) | (m) | 102.08× | Reported |
| 2015-03-31 | $3.21M | (m) | $1.84M | $11.48M | $323.00K | (m) | (m) | 35.54× | Reported |
| 2014-12-31 | $2.98M | (m) | $1.45M | $10.51M | $449.00K | (m) | (m) | 23.41× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $2.26M | (m) | $60.00K | $829.00K | $493.00K | (m) | (m) | 1.68× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Conexeu Sciences Inc. (CNXU) | United States | $0.111B | |
| NutriBand Inc. (NTRB) | United States | $0.109B | |
| LAKELAND INDUSTRIES INC (LAKE) | United States | $0.104B | -4.21 |
| Safe Pro Group Inc. (SPAI) | United States | $0.090B | |
| MYOMO, INC. (MYO) | United States | $0.065B | -2.85 |
| Envoy Medical, Inc. (COCH) | United States | $0.056B | |
| ALPHA PRO TECH LTD (APT) | $0.052B | 13.63 | |
| MILESTONE SCIENTIFIC INC. (MLSS) | United States | $0.036B | -6.85 |
| Lifeward Ltd. (LFWD) | $0.021B | ||
| ENvue Medical, Inc. (FEED) | United States | $0.011B |